GenMont Biotech Incorporation
Quick facts
Phase 3 pipeline
- eN-Lac® · Infectious Diseases
eN-Lac is a recombinant human lactoferrin used to treat various infections.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about GenMont Biotech Incorporation
What is GenMont Biotech Incorporation's pipeline?
GenMont Biotech Incorporation has 1 drugs in Phase 3, 0 in Phase 2, 2 in Phase 1. Late-stage candidates include eN-Lac®.
Related
- Sector hub: All tracked pharma companies